AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg QD
Number of subjects: 928
Study 23471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 200 mg QD
Number of subjects: 928
Study 23471546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 928
Study 23471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (all doses)
Number of subjects: 928
Study 23471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg and 200 mg
Number of subjects: 928
Study 20855387 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group (rectal temperature of 33.5°C for 72 hours)
Number of subjects: 129
Study 20855387 — intervention group
Group type: COMPARATOR
Intervention: Normothermia group (rectal temperature of 37°C)
Number of subjects: 129
Study 20855387 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group (severe HIE subgroup)
Number of subjects: 129
Study 18774745 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 527
Study 18774745 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 527
Study 17214385 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal shaking of the vessel containing liquid
Number of subjects: 0
Study 17214385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical lifting of the vessel containing liquid
Number of subjects: 0
Study 17214385 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaking the vessel containing liquid and solid
Number of subjects: 0
Study 12398952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium milk powder (800 mg of calcium)
Number of subjects: 100
Study 10493473 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week community-based arthritis self-management program
Number of subjects: 331
Study 10493473 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 4-month changes in self-efficacy
Number of subjects: 331
Study 8528479 — intervention group
Group type: EXPERIMENTAL
Intervention: Videonystagmoscopy
Number of subjects: 0
Study 8528479 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, age-matched volunteers)
Number of subjects: 0
Study 1722834 — intervention group
Group type: EXPERIMENTAL
Intervention: Honvan (diethylstilbestrol diphosphate) 300 mg/day
Number of subjects: 53
Study 1722834 — intervention group
Group type: EXPERIMENTAL
Intervention: Estracyt (estramustine phosphate) 560 mg/day
Number of subjects: 53
Study 1722834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostal (chlormadinone acetate) 100 mg/day
Number of subjects: 53
Study 1722834 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration plus MTX (methotrexate) 20 mg/m2 every 2 weeks
Number of subjects: 53
Study 1722834 — intervention group
Group type: COMPARATOR
Intervention: Castration alone
Number of subjects: 53
Study 1722834 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration plus CPM (cyclophosphamide) 0.5-1 g/m2 every 3-4 weeks
Number of subjects: 53
Study 7114938 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple closure
Number of subjects: 101
Study 7114938 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (VD)
Number of subjects: 101
Study 7114938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with closure (PGV)
Number of subjects: 101
Study 7114938 — intervention group
Group type: COMPARATOR
Intervention: VD
Number of subjects: 101
Study 7114938 — intervention group
Group type: COMPARATOR
Intervention: PGV
Number of subjects: 101
Study 30779119 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention program (n = 40 adolescents, 14 females)
Number of subjects: 79
Study 30779119 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control condition (n = 39 adolescents, 20 females)
Number of subjects: 79
Study 29348711 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin ear drops plus oral placebo
Number of subjects: 100
Study 29348711 — intervention group
Group type: COMPARATOR
Intervention: Combined oral and topical ciprofloxacin
Number of subjects: 100
Study 27164312 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional memory training (Group 1)
Number of subjects: 77
Study 27164312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumosity (Group 2)
Number of subjects: 77
Study 27164312 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional memory training and Lumosity (Group 3)
Number of subjects: 77
Study 27164312 — intervention group
Group type: COMPARATOR
Intervention: No training (Group 4)
Number of subjects: 77
Study 24243927 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic nasal saline irrigation
Number of subjects: 127
Study 24243927 — intervention group
Group type: COMPARATOR
Intervention: Isotonic nasal saline spray
Number of subjects: 127
Study 22185494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial recordings from the fusiform gyrus
Number of subjects: 8
Study 22185494 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic faces; happy, neutral, and fearful expressions
Number of subjects: 8
Study 20651414 — intervention group
Group type: EXPERIMENTAL
Intervention: Western exercise (WE)
Number of subjects: 132
Study 20651414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 132
Study 20651414 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 132
Study 18756344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg per day for three days
Number of subjects: 50
Study 18756344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18756344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50
Study 15966882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish
Number of subjects: 16
Study 15966882 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 16
Study 12806591 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg + Lisinopril 20 mg
Number of subjects: 80
Study 12806591 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg (maximum recommended dose)
Number of subjects: 80
Study 10735266 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical guidelines
Number of subjects: 0
Study 10735266 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8840293 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (new model of hemodialysis potassium removal)
Number of subjects: 42
Study 8840293 — intervention group
Group type: COMPARATOR
Intervention: Treatment A (standard hemodialysis)
Number of subjects: 42
Study 1611114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU interferon-alpha 2b
Number of subjects: 44
Study 1611114 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 MU interferon-alpha 2b
Number of subjects: 44
Study 1611114 — intervention group
Group type: COMPARATOR
Intervention: 1.3 g ethoglucid
Number of subjects: 44
Study 6560416 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1 for administering subcutaneous low-dose heparin
Number of subjects: 43
Study 6560416 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 for administering subcutaneous low-dose heparin
Number of subjects: 43
Study 6560416 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 3 for administering subcutaneous low-dose heparin
Number of subjects: 43
Study 31502862 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 1383
Study 31502862 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1383
Study 30851434 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and postpartum lifestyle interventions
Number of subjects: 300
Study 30851434 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 300
Study 30851434 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal intervention to moderate GWG and introduce skills for weight management
Number of subjects: 300
Study 30851434 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum intervention addressing weight loss
Number of subjects: 300
Study 29221967 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation (CCR) using Erica software
Number of subjects: 35
Study 29221967 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 27574838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg
Number of subjects: 622
Study 27574838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg
Number of subjects: 622
Study 27574838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 24332668 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt (MBTS)
Number of subjects: 549
Study 24332668 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt (RVPAS)
Number of subjects: 549
Study 22984128 — intervention group
Group type: COMPARATOR
Intervention: Open technique (n = 33)
Number of subjects: 67
Study 22984128 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic technique (n = 34)
Number of subjects: 67
Study 19948523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 40
Study 19948523 — intervention group
Group type: COMPARATOR
Intervention: Bi-level nasal CPAP
Number of subjects: 40
Study 18497320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue anticoagulants for 9 additional months (RVT group)
Number of subjects: 258
Study 18497320 — intervention group
Group type: COMPARATOR
Intervention: Stop anticoagulants (RVT group)
Number of subjects: 258
Study 18497320 — intervention group
Group type: COMPARATOR
Intervention: No RVT (stop OAT)
Number of subjects: 258
Study 18497320 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue OAT (RVT group)
Number of subjects: 258
Study 18497320 — intervention group
Group type: COMPARATOR
Intervention: Stop OAT (RVT group)
Number of subjects: 258
Study 15625070 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 92
Study 15625070 — intervention group
Group type: COMPARATOR
Intervention: 4.25% dextrose
Number of subjects: 92
Study 12574190 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (group A)
Number of subjects: 40
Study 12574190 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (group B)
Number of subjects: 40
Study 12574190 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (group C)
Number of subjects: 40
Study 12574190 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐65 mg iodide daily for 60 days (all groups)
Number of subjects: 40
Study 12574190 — intervention group
Group type: EXPERIMENTAL
Intervention: After iodine withdrawal (all groups)
Number of subjects: 40
Study 12574190 — intervention group
Group type: COMPARATOR
Intervention: 60‐65 mg iodide daily for 60 days (group D)
Number of subjects: 40
Study 10417466 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 microgram.kg‐1)
Number of subjects: 60
Study 10417466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.15 mg.kg‐1)
Number of subjects: 60
Study 10417466 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 60
Study 8745846 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow measurements (weekly)
Number of subjects: 131
Study 8745846 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 measurements (every six months in a laboratory)
Number of subjects: 131
Study 1906004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 19-6327 (10 to 50 mg oral pre-dose)
Number of subjects: 8
Study 1906004 — intervention group
Group type: COMPARATOR
Intervention: L‐deprenyl (tracer alone)
Number of subjects: 8
Study 6728127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2.5, 5.0 and 10.0 micrograms/kg)
Number of subjects: 0
Study 6728127 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.5 and 3.0 micrograms/kg)
Number of subjects: 0
Study 6728127 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 0
Study 30138612 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced education via SMS (4 days before colonoscopy)
Number of subjects: 0
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: School Entry Screening (SHS)
Number of subjects: 668
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Audiology referrals
Number of subjects: 668
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: SHS program
Number of subjects: 668
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: SHS referral rates
Number of subjects: 668
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: SHS referral percentage
Number of subjects: 668
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiology services
Number of subjects: 668
Study 29504414 — intervention group
Group type: EXPERIMENTAL
Intervention: UNHS children born after 2011
Number of subjects: 668
Study 26297940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga group (n = 61)
Number of subjects: 118
Study 26297940 — intervention group
Group type: COMPARATOR
Intervention: Stretching-strengthening exercise group (n = 57)
Number of subjects: 118
Study 24569690 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra) at a dose of 100 mg subcutaneously once a day for 5 days
Number of subjects: 20
Study 24569690 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra)
Number of subjects: 20
Study 22286159 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 22286159 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 20329654 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS/HCTZ (losartan 50 mg/day + hydrochlorothiazide 12.5 mg/day)
Number of subjects: 42
Study 20329654 — intervention group
Group type: EXPERIMENTAL
Intervention: TEL/HCTZ (telmisartan 40 mg/day + hydrochlorothiazide 12.5 mg/day)
Number of subjects: 42
Study 20329654 — intervention group
Group type: EXPERIMENTAL
Intervention: CND/HCTZ (candesartan 8 mg/day + hydrochlorothiazide 12.5 mg/day)
Number of subjects: 42
Study 17097378 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 835
Study 17097378 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 835
Study 17097378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study 17293386 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated family presence
Number of subjects: 30
Study 17293386 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 30
Study 17293386 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (horticultural text reading)
Number of subjects: 30
Study 17293386 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 14741060 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d donepezil
Number of subjects: 12
Study 14741060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11707842 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (cyclophosphamide/doxorubicin/vincristine/prednisone)
Number of subjects: 0
Study 11707842 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factors added to CHOP chemotherapy
Number of subjects: 0
Study 11707842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy followed by autologous stem cell transplantation
Number of subjects: 0
Study 11707842 — intervention group
Group type: EXPERIMENTAL
Intervention: New lymphoma treatments with improved toxicity profiles
Number of subjects: 0
Study 9394365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (Zinecard)
Number of subjects: 150
Study 9394365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 150
Study 7506168 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (300 mg/day)
Number of subjects: 660
Study 7506168 — intervention group
Group type: COMPARATOR
Intervention: naproxen (750 mg/day)
Number of subjects: 660
Study 3822278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine plus magnesium sulfate (N = 38)
Number of subjects: 74
Study 3822278 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine (N = 36)
Number of subjects: 74
Study 31104485 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥27.5 kg/m2
Number of subjects: 3847
Study 31104485 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference >100 cm (men) or >90 cm (women)
Number of subjects: 3847
Study 31104485 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds of BMI and waist circumference
Number of subjects: 3847
Study 31104485 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of BMI and waist circumference below thresholds
Number of subjects: 3847
Study 27620990 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 80
Study 27620990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27620990 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (in participants without diabetes mellitus)
Number of subjects: 80
Study 27620990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in participants without diabetes mellitus)
Number of subjects: 80
Study 26457580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin 2 mg subcutaneously daily for 6 months
Number of subjects: 806
Study 26457580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study 23712593 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury from trauma exposure
Number of subjects: 236
Study 23712593 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender, assault, perceived life threat, and peritraumatic dissociation
Number of subjects: 236
Study 23712593 — intervention group
Group type: COMPARATOR
Intervention: Model without injury
Number of subjects: 236
Study 21054683 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 123
Study 21054683 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 123
Study 18838243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention based on self-determination theory
Number of subjects: 0
Study 18838243 — intervention group
Group type: COMPARATOR
Intervention: Community care
Number of subjects: 0
Study 17425627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 or 10 microg) injected subcutaneously
Number of subjects: 31
Study 17425627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg q.d.)
Number of subjects: 31
Study 17425627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 or 10 microg)
Number of subjects: 31
Study 17425627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 and 10 microg)
Number of subjects: 31
Study 14691039 — intervention group
Group type: EXPERIMENTAL
Intervention: Running wheels (5.1+/‐0.8 km/d)
Number of subjects: 19
Study 14691039 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training for 28 days
Number of subjects: 19
Study 11744430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/day oral ganciclovir
Number of subjects: 281
Study 11744430 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g/day oral ganciclovir
Number of subjects: 281
Study 11744430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 g/day oral ganciclovir
Number of subjects: 281
Study 11744430 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg/day IV ganciclovir
Number of subjects: 281
Study 9830246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypochondriasis
Number of subjects: 493
Study 9830246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with somatization syndrome
Number of subjects: 493
Study 9830246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple somatization symptoms
Number of subjects: 493
Study 9830246 — intervention group
Group type: COMPARATOR
Intervention: Clinical control group (other mental disorders)
Number of subjects: 493
Study 9830246 — intervention group
Group type: COMPARATOR
Intervention: Nonclinical controls
Number of subjects: 493
Study 7857998 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise classes (n = 87)
Number of subjects: 261
Study 7857998 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis participants (n = 63)
Number of subjects: 261
Study 7857998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis participants (n = 24)
Number of subjects: 261
Study 7857998 — intervention group
Group type: COMPARATOR
Intervention: Rheumatoid arthritis patients (n = 48)
Number of subjects: 261
Study 2479303 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine, 240 mg
Number of subjects: 12
Study 2479303 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine, 120 mg
Number of subjects: 12
Study 2479303 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 12
Study 31290344 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2-3 mg/day
Number of subjects: 1853
Study 31290344 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 1-3 mg/day
Number of subjects: 1853
Study 31290344 — intervention group
Group type: COMPARATOR
Intervention: ADT + placebo
Number of subjects: 1853
Study 28830875 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption (YesB)
Number of subjects: 36
Study 28830875 — intervention group
Group type: COMPARATOR
Intervention: Breakfast omission (NoB)
Number of subjects: 36
Study 26255512 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zusanli (ST 36) combined with oral administration of Gexia Zhuyu decoction
Number of subjects: 120
Study 26255512 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment combined with oral administration of Gexia Zhuyu decoction
Number of subjects: 120